

1 Rhinovirus infection of airway epithelial cells uncovers the non-ciliated subset as a
2 likely driver of genetic susceptibility to childhood-onset asthma.

3
4 Sarah Djeddi^{ε,1,2,3}, Daniela Fernandez-Salinas^{ε,1,2,3,4}, George X. Huang^{5,6}, Vitor R. C. Aguiar^{1,2,3},
5 Chitrasen Mohanty¹⁰, Christina Kendzioriski¹⁰, Steven Gazal^{7,8}, Joshua Boyce^{5,6}, Carole Ober⁹,
6 James Gern^{10,11}, Nora Barrett^{5,6}, Maria Gutierrez-Arcelus*^{1,2,3}

7
8 ε These authors contributed equally to this work.

9 ¹Division of Immunology, Boston Children's Hospital, Boston, MA, USA

10 ²Department of Pediatrics, Harvard Medical School, Boston, MA, USA

11 ³Broad Institute of MIT and Harvard, Cambridge, MA, USA

12 ⁴Licenciatura en Ciencias Genómicas, Instituto de Biotecnología, Universidad Nacional Autónoma
13 de México (UNAM), Cuernavaca, Morelos, México.

14 ⁵Department of Medicine, Harvard Medical School, Boston, MA, USA

15 ⁶Jeff and Penny Vinik Center for Allergic Disease Research, Division of Rheumatology,
16 Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA.

17 ⁷Department of Quantitative and Computational Biology, University of Southern California

18 ⁸Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California

19 ⁹Department of Human Genetics, University of Chicago, Chicago, Ill, USA.

20 ¹⁰Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison,
21 Madison, WI, USA.

22 ¹¹Departments of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public
23 Health, Madison, WI, USA

24
25 *Corresponding author:

26
27 Maria Gutierrez-Arcelus

28 Boston Children's Hospital

29 Division of Immunology

30 Karp Family Research Laboratories, Room 102016.1

31 1 Blackfan Circle

32 Boston, MA, 02115

33 mgutierr@broadinstitute.org

34 857-559-3229

35

36

37

38 Abstract

39

40 Asthma is a complex disease caused by genetic and environmental factors. Epidemiological
41 studies have shown that in children, wheezing during rhinovirus infection (a cause of the common
42 cold) is associated with asthma development during childhood. This has led scientists to
43 hypothesize there could be a causal relationship between rhinovirus infection and asthma or that
44 RV-induced wheezing identifies individuals at increased risk for asthma development. However,
45 not all children who wheeze when they have a cold develop asthma. Genome-wide association
46 studies (GWAS) have identified hundreds of genetic variants contributing to asthma
47 susceptibility, with the vast majority of likely causal variants being non-coding. Integrative
48 analyses with transcriptomic and epigenomic datasets have indicated that T cells drive asthma
49 risk, which has been supported by mouse studies. However, the datasets ascertained in these
50 integrative analyses lack airway epithelial cells. Furthermore, large-scale transcriptomic T cell
51 studies have not identified the regulatory effects of most non-coding risk variants in asthma
52 GWAS, indicating there could be additional cell types harboring these “missing regulatory
53 effects”. Given that airway epithelial cells are the first line of defense against rhinovirus, we
54 hypothesized they could be mediators of genetic susceptibility to asthma. Here we integrate
55 GWAS data with transcriptomic datasets of airway epithelial cells subject to stimuli that could
56 induce activation states relevant to asthma. We demonstrate that epithelial cultures infected
57 with rhinovirus significantly upregulate childhood-onset asthma-associated genes. We show that
58 this upregulation occurs specifically in non-ciliated epithelial cells. This enrichment for genes in
59 asthma risk loci, or ‘asthma heritability enrichment’ is also significant for epithelial genes
60 upregulated with influenza infection, but not with SARS-CoV-2 infection or cytokine activation.
61 Additionally, cells from patients with asthma showed a stronger heritability enrichment
62 compared to cells from healthy individuals. Overall, our results suggest that rhinovirus infection
63 is an environmental factor that interacts with genetic risk factors through non-ciliated airway
64 epithelial cells to drive childhood-onset asthma.

65 Introduction

66 Asthma is a complex and heterogeneous disease that affects 300 million children and adults
67 worldwide and represents a significant burden to healthcare (\$82 billion for the US in 2013) ¹. It
68 is characterized by inflammation of the airways leading to recurrent episodes of airflow
69 obstruction and symptoms such as wheezing, shortness of breath and coughing. Asthma patients
70 have impairments of epithelial barrier function, manifested by irregular disruption of the tight
71 junctions, detachment of ciliated cells and reduced expression of cell-cell adhesion molecules
72 (for instance, E-cadherin) ². This barrier disruption allows environmental substances like
73 allergens, viruses, bacteria and toxic substances to penetrate the submucosa more easily.
74 Allergens, viral infections, and type 2 inflammation have been shown to further damage the
75 barrier integrity of the airway epithelium; moreover, they trigger asthma exacerbations ³.
76 Longitudinal epidemiological studies have shown that wheezing caused by rhinovirus infection in
77 children is a risk factor for developing asthma later in childhood ⁴⁻⁶. These observations have led
78 to two hypotheses: (1) rhinovirus infection could be causal in asthma development or (2)
79 rhinovirus-induced wheeze is a biomarker that identifies children at increased risk for asthma
80 development. In some children, rhinovirus wheezing does not lead to asthma.

81
82 Genome-wide association studies (GWAS) have discovered more than 100 risk loci for asthma ^{7,8}.
83 Similar to other complex diseases, the vast majority of the likely causal risk variants are non-
84 coding. As a consequence, deciphering the mechanisms through which the risk alleles lead to
85 disease is challenging; it has been achieved for only a small minority of risk loci. Using a suite of
86 recently developed methods that integrate GWAS data with functional genomics datasets,
87 investigators have discovered key cell types that mediate the genetic susceptibility to complex
88 diseases. For example, risk variants for rheumatoid arthritis are enriched in regulatory elements
89 specific for CD4 T cells, and studies in patients and mice have shown the relevance of these cells
90 in the pathogenesis of this disease ⁹⁻¹³. Additionally, GWAS integration with transcriptomics
91 revealed that a significant proportion of the risk alleles for Alzheimer's disease act through the
92 myeloid lineage rather than the brain ¹⁴. Alzheimer's disease is now considered an immune-

93 mediated disease ^{14,15}. For asthma, T cell-specific regulatory elements and gene expression are
94 enriched in genetic risk loci ^{12,13,16,17}, with some highlighting particularly Th2 cells consistent with
95 the role of type 2 inflammation in asthma pathogenesis ^{18–21}.

96
97 The observations that non-coding risk variants affect gene regulation in cell types relevant to
98 each disease have motivated large-scale transcriptomic studies to identify genetic variants that
99 are associated with both gene expression (expression quantitative trait loci, eQTL) and disease
100 risk. However, only 25-40% of risk variants for immune-mediated diseases co-localize with eQTLs
101 in immune cells ^{22–24}. For asthma, alleles at only 47% of loci co-localize with leukocyte expression
102 and/or splicing QTLs ²². Hence, the regulatory effects of most non-coding risk variants remain
103 unknown. More recent studies have highlighted that these “missing regulatory effects” could be
104 hidden in specific activation or differentiation cell states that haven’t been systematically
105 ascertained ^{25–28}.

106
107 GWAS enrichment studies have been highly biased towards annotations of blood immune cell
108 types, with reduced resolution when using other tissues relevant to the context of asthma, such
109 as GTEx tissues from post-mortem human organs ^{11,13,16,29,30}. Here we sought to define whether
110 airway epithelial cell states could be driving genetic susceptibility to asthma. We analyzed 10
111 single-cell and bulk transcriptomic datasets of epithelial cells subject to different activation
112 conditions. We integrated these datasets with GWAS summary statistics for childhood-onset
113 asthma (COA), adult-onset asthma (AOA), unspecified-onset asthma (henceforth referred to as
114 all asthma), and a genetically correlated type 2 inflammation trait: allergy/eczema
115 (**Supplementary Table 1**) ^{31–33}. We additionally tested three control traits to assess the specificity
116 of our findings. We used state of the art methods that control for linkage disequilibrium, take
117 advantage of most ascertained genetic variants in the genome, and have been shown to work
118 well for bulk and single cell datasets ^{13,17}.

119 Results

120 We applied two methods that use GWAS data to identify relevant cell types for disease. Linkage
121 Disequilibrium Score-regression in Specifically Expressed Genes (LDSC-SEG) identifies heritability
122 enrichment in genomic annotations (such as genes or chromatin marks with specific presence in
123 a particular cell type or cell state)¹³. Single-cell disease-relevance score (scDRS) identifies cells,
124 from single-cell RNA-seq data, that significantly express genes in GWAS loci (weighted according
125 to their strength of association with disease) relative to null sets of control genes in the same
126 dataset¹⁷. We retrieved GWAS summary statistics from asthma related traits as described above.
127 Throughout our analyses we included three complex traits as controls: height, as a non-immune
128 control, Alzheimer's disease (AD) as a trait implicating myeloid cells, and rheumatoid arthritis
129 (RA) as a lymphocyte-driven disease with a strong T cell component^{11,13,16,17,29}.

130

131 T cell validation

132 First, we sought to validate T-cell involvement in the genetic susceptibility to asthma, as
133 previously reported in the literature^{13,16,17,29}. Applying LDSC-SEG to bulk ATAC-seq data of human
134 peripheral blood leukocyte populations, we confirmed that T-cell specific open chromatin regions
135 are significantly enriched in heritability for asthma-related traits (**Supplementary Figure 1**)¹⁶.
136 Furthermore, when comparing cell types between their resting and activated state, we confirmed
137 that activation-specific open chromatin in T cells has significant heritability enrichment for all the
138 asthma-related traits (**Supplementary Figure 1E**). Next, we applied scDRS to single-cell RNA-seq
139 datasets to identify cells with significant over-expression of risk genes identified from GWAS
140 studies (see Methods). In sinonasal mucosa tissue from healthy donors and chronic rhinosinusitis
141 patients, we observed that 21-83% of cells with significant disease relevant score (10% FDR) for
142 asthma-related traits are T cells (**Supplementary Figure 2**). In a dataset of house dust mite-
143 activated T cells from asthma and allergic patients, we observed that among the cells with
144 significant disease relevant score, most were T effector and Th2 cells (51-57% and 48-42%
145 respectively, **Supplementary Figure 3**). Overall, these analyses confirm the validity of the

146 methods used for this study and confirm previous findings showing the relevance of T cells in the
147 genetic susceptibility to asthma-related traits.

148

149 **Rhinovirus infection induces upregulation of asthma-associated genes in epithelial cells from**
150 **healthy donors.** To assess the role that rhinovirus infection could play in asthma genetic
151 susceptibility at the epithelial cell level, we analyzed a publicly available bulk RNA-seq data of
152 basal airway epithelial cells from healthy donors (N=9) that were infected in vitro with RV-A16
153 (rhinovirus species RV-A, subtype 16) or treated with PBS vehicle control (**Figure 1A**)³⁴. Using a
154 linear mixed model, we performed differential expression analysis (DEA) testing for rhinovirus
155 infection versus PBS vehicle. From the 14,883 tested genes, we selected the top 10% based on t-
156 statistic (as recommended by LDSC-SEG) to select genes that are upregulated with rhinovirus
157 infection(**Figure 1B**). We used LDSC-SEG to investigate whether this gene set showed an
158 enrichment of asthma heritability. Our analysis showed significant heritability enrichment in
159 rhinovirus-upregulated genes for all asthma (P = 0.033) and COA (P = 0.037), with a larger
160 coefficient observed for COA (**Figure 1C**). Moreover, we did not observe any significant
161 enrichment for any of the control traits (AD, RA, height) (**Supplementary Figure 4A**). The fact that
162 we did not observe significant heritability enrichment in RV-upregulated genes for RA suggests
163 that the signal observed for all asthma and COA is not due to a general immune transcriptional
164 response, but rather a response that is specific for RV-infection of epithelial cells.

165

166 Next, we sought to validate these findings in an independent study using a different strain of RV.
167 We reanalyzed a bulk RNA-seq time course dataset of epithelial cells from 3 healthy donors
168 where cells were infected with RV-C15, and samples were collected before infection and at 12,
169 24, and 42 hours post-infection (HPI) (**Figure 1D**)³⁵. We performed differential expression
170 analysis to identify genes upregulated specifically in each time point (versus all others), and
171 applied LDSC-SEG (**Supplementary Figure 4B**). We observed significant heritability enrichment
172 for upregulated genes by rhinovirus infection specifically at 24 hours for all asthma-related traits
173 (P < 0.05, **Figure 1E**). This enrichment was higher for COA and allergy/eczema, compared to all
174 asthma and AOA (**Figure 1E**). Genes that were specifically expressed at 42 hours post-infection

175 also had positive enrichment for heritability in all traits, but this was only significant for
176 allergy/eczema ($P = 0.03$). Once again, this enrichment was not present in any of the control traits
177 (**Supplementary Figure 4C**). Together, these findings suggest that rhinovirus-infected epithelial
178 cells represent a cell state that may mediate genetic susceptibility to asthma, with a greater
179 contribution to COA than to AOA.

180

181 **Asthma-associated genes after rhinovirus infection are specifically enriched in non-ciliated**
182 **epithelial cells.** We then asked whether there were specific epithelial cell subsets that may
183 mediate asthma genetic risk after rhinovirus infection. To evaluate this, we used single-cell RNA-
184 seq data of 3 healthy donors, where airway epithelial cell samples were infected with RV-C15 or
185 resting and profiled at 24 hours (**Figure 2A, Supplementary Figure 5A-C**). We performed cell
186 clustering and then annotated the clusters based on epithelial cell markers (**Supplementary**
187 **Figure 5D**). We identified 2 ciliated cell subsets, and 5 non-ciliated cell subsets: basal,
188 deuterosomal, neuroendocrine, secretory, and transitional (**Figure 2B, Supplementary Figure**
189 **5D**). We applied scDRS on this dataset to identify cells with significant over-expression of asthma-
190 associated genes. The number of cells with significant disease relevant scores (10% FDR) varied
191 per trait: 147 cells for all asthma, 850 cells for COA, 0 for AOA and 147 cells for allergy/eczema
192 (**Figure 2C**). Notably, COA was the trait with the highest proportion of disease-relevant cells.
193 Among the cells with a significant disease relevant score, 99% corresponded to the stimulated
194 condition. Furthermore, the disease relevant cells were strongly over-represented in the non-
195 ciliated cell subsets, representing 96-99% of the significant cells, while they make up 25% of the
196 whole dataset (**Figure 2C-D**). As expected, we did not observe any significant cells for height, AD
197 and RA (**Supplementary Figure 5E**).

198

199 Overall, we identified non-ciliated cells as the main epithelial cell subset with significant
200 upregulation of childhood-onset asthma-associated genes after rhinovirus infection. However,
201 only ciliated cells are known to be infected by RV-C15, which we confirmed by looking at the
202 expression of the RV-15 receptor (*CDHR3*) and the presence of the viral sequence itself in the
203 scRNA-seq data³⁶ (**Supplementary Figure 5F-G**). We therefore hypothesized that ciliated cells

204 may communicate with non-ciliated cells upon rhinovirus infection. We used CellphoneDB to
205 investigate some of the possible ligand-receptor mechanisms through which cells may be
206 communicating³⁷. Specifically, we looked for ligand-encoding genes expressed in ciliated cells
207 and their corresponding receptor-encoding gene expressed in non-ciliated cells. Furthermore, we
208 required that the ciliated cell ligand-encoding gene is upregulated upon rhinovirus infection. We
209 identified a potential pair of interactors consisting of *LGALS9*, which codes for a galectin from the
210 beta-galactoside-binding protein family implicated in the modulation of the cell-cell and cell-
211 matrix interactions, and *SORL1*, a gene encoding sortilin-related receptor, which may have a role
212 in endocytosis and intracellular trafficking (**Supplementary Figure 5H-I**).

213

214 **Enrichment of asthma-associated genes after rhinovirus infection is strong in epithelial cells**

215 **from asthma patients.** Having observed the enrichment of asthma-associated genes after RV
216 infection in both bulk and single-cell level in healthy subjects, we asked whether we would
217 observe the same enrichment in samples coming from asthma patients. To do this, we repeated
218 the differential expression analysis between rhinovirus RV-A16 infection and treatment with PBS
219 from the first dataset³⁴, this time using the asthma patient cohort (**Figure 3A**). We found 2,843
220 differentially expressed genes at 5% FDR, 1,353 of them upregulated and 1,481 downregulated
221 after RV infection (**Figure 3B**). Of the 2,843 differentially expressed genes in patients, 1,834 were
222 also differentially expressed in healthy controls. After selecting the top 10% genes by t-statistic
223 (1,488) and running LDSC-SEG, we observed significant heritability enrichment for all asthma (P
224 = 0.003) and COA (P = 0.003, **Figure 3C**). We did not observe heritability enrichment for down-
225 regulated genes by RV (P > 0.05, **Supplementary Figure 6C**). While the results were consistent
226 with what we observed in healthy controls (COA τ^* =0.17, all asthma τ^* = 0.15), the enrichment
227 of RV-upregulated asthma-associated genes was more significant and had a larger enrichment
228 coefficient in the asthma patients (COA τ^* =0.32, all asthma τ^* =0.25).

229

230 Based on these results, we hypothesized that asthma patients might have airway epithelial cells
231 in a transcriptomic state that over-expresses asthma-risk genes in comparison to healthy
232 controls, which might be linked to or independent of their response to RV. To test this, we

233 analyzed differentially expressed genes between asthma patients and healthy individuals taking
234 all samples while controlling for RV/PBS treatment. We found 994 differentially expressed genes
235 between patients and controls (5% FDR, **Figure 3D**). After selecting the top 10% genes
236 upregulated in patients based on t-statistic (1,593), we found a suggestive significant enrichment
237 for COA heritability ($P = 0.05$, **Figure 3E**). As expected, our control traits did not have any
238 significant heritability enrichment for either of the annotations tested (**Supplementary Figure 6**).
239 Overall, these results suggest that the epithelial cells from patients could be in a state that is
240 over-expressing asthma-associated genes.

241
242 **Genes at asthma risk loci upregulated with rhinovirus infection in airway epithelial cells.** We
243 then investigated which of the genes upregulated by rhinovirus infection are associated with COA
244 and AOA. To do so, we retrieved the GWAS lead variants identified by Ferreira et al.³⁸. We then
245 linked risk variants to genes using three approaches: (1) selecting the likely target genes identified
246 by the locus-to-gene (L2G) algorithm of Open Targets Genetics, herein called L2G genes, (2)
247 selecting the closest gene to the lead variant, and (3) selecting genes within a 250kb window of
248 the lead variant (see Methods). From these gene lists, we selected genes that were upregulated
249 upon rhinovirus infection in epithelial cells at 5% FDR (**Figure 4**)^{34,35}. For COA we identified 55
250 risk loci with genes upregulated upon rhinovirus infection in epithelial cells, 13 of which have L2G
251 likely target genes (e.g. *IL1RL1*, *IL4R*, *GSDMB*, *OVOL1*, *MYC*), and 6 are the closest gene to the
252 lead variant (e.g. *IRF1*, *GPR183*). For AOA only 19 risk loci have genes upregulated by RV in
253 epithelial cells, among which 3 are likely target genes (e.g. *IL4R*, *HDAC7*, *IL1RL1*) and 3 are the
254 closest gene to the lead variant (e.g. *RAPGEF3*, *IRF1*, *SSR3*). Few genes were shared between COA
255 and AOA (*IRF1*, *IL4R*, *PDLIM4*, *IL1R2* and *IL1RL1*).

256
257 After having characterized the asthma-associated genes that are upregulated in RV-infected
258 epithelial cells, we sought to define which of these genes are shared with T cells. To do so, we
259 compared the levels of expression of the genes in the RV-datasets with a dataset we previously
260 published consisting of 8 activation time points of human periphery memory CD4+ T cells
261 stimulated with anti-CD3/CD28 microbeads²⁵. One of the highlighted genes that also had an

262 increased expression in T cells was *MYC*, with an increase at 2 and 4 hours post-stimulation.
263 Notably, this gene's expression was not only increased after rhinovirus infection within asthma
264 patients ($P=0.01$) and within healthy controls ($P=0.0009$) but was also upregulated in patients
265 compared to controls ($P=0.01$). On the other hand, *OVOL1*, another GWAS gene upregulated in
266 RV-infected epithelial cells, shows the same pattern of expression as *MYC* in epithelial cells, but
267 shows almost no expression in T cells (**Figure 4B, Supplementary Figure 7**). *OVOL1* is also
268 associated with atopic dermatitis, another type 2 inflammatory disease and a recent meta-
269 analysis study confirmed this susceptibility locus for eczema-associated asthma³⁹.

270

271 **Other viral infections in epithelial cells and their association with asthma susceptibility.**

272 We next asked whether other viruses could potentially be inducing upregulation of asthma-
273 associated genes in epithelial cells. First, we analyzed a bulk RNA-seq dataset of bronchial
274 epithelial cells stimulated by influenza A virus at 48 hours or sham control ($N = 3$ healthy donors,
275 **Figure 5A**). We identified differentially expressed genes between influenza A and the sham
276 control and we selected the top 10% upregulated genes ranked by a t-statistic to run LDSC-SEG
277 (**Supplementary Figure 8A**). The results show a significant enrichment of heritability for the four
278 asthma-related traits ($P < 0.05$), suggesting that influenza A infection also significantly
279 upregulates asthma and allergy-associated genes (**Figure 5B**). We did not observe any significant
280 enrichment for the control traits (**Supplementary Figure 8B**).

281

282 Subsequently, we analyzed a single-cell RNA-seq dataset of immune and non-immune cells
283 obtained by nasopharyngeal swabs from COVID-19 patients or healthy donors ($N=58$, **Figure 5C-
284 D**)⁴⁰. We identified cells with significant disease-relevant scores at 10% FDR, among which we
285 found 174 cells for AOA, 795 cells for COA, 594 for allergy/eczema and 280 for all asthma (**Figure
286 5E**). COA yielded the highest number of disease relevant cells. We observed an increase in
287 proportions of enriched cells for T cells in all traits and for squamous cells in COA, allergy/eczema
288 and all asthma (**Figure 5F**). More precisely, T cells which represented 5% of the cells in the
289 dataset, constituted 78% of significant cells for AOA, 11% for COA, 42% for allergy/eczema and
290 61% for all asthma (**Figure 5F**). The COVID-19 status did not have any significant impact on the

291 asthma-associated expression, as the disease-relevant cells were not overrepresented in any
292 specific patient group (**Figure 5G**). As expected, we observed an enrichment for the macrophages
293 cluster in Alzheimer's and T cells cluster in rheumatoid arthritis (**Supplementary Figure 8C**).
294 Additionally, we analyzed a dataset of bronchial epithelial cells (BECs) infected with SARS-CoV-2
295 in vitro, and profiled with scRNA-seq after one, two or three days, along with non-infected cells
296 (N = 1 healthy control, **Supplementary Figure 9A-B**). We clustered and annotated ciliated and
297 non-ciliated cell subsets, and applied scDRS for the four asthma-related traits (**Supplementary**
298 **Figure 9C-D**). We identified cells with significant disease-relevant scores at 10% FDR, finding 3
299 cells for AOA, 802 cells for COA, 243 cells for allergy/eczema and 621 cells for all asthma
300 (**Supplementary Figure 9D-E**). The disease relevant cells were strongly over-represented in the
301 non-infected cells subsets, constituting 62-89% of the significant cells (**Supplementary Figure 9F**).
302 Overall, these findings indicate that the influenza virus significantly induces the expression of
303 asthma-associated genes, whereas SARS-CoV-2 does not.

304

305 **Epithelial cells activated with cytokines relevant for type 2 inflammation.**

306 Both epithelial and immune cells respond to cytokines by upregulating signaling pathways that
307 drive inflammation. Some pro-inflammatory cytokines relevant to asthma are IL-4, IL-13, IL-17
308 and interferon (IFN γ). These cytokines are upregulated in subsets of patients with severe or type
309 2 asthma ⁴¹⁻⁴⁶. Moreover, blockade of IL4R α is a highly effective treatment for moderate to
310 severe asthma ⁴⁷. Consequently, we asked whether epithelial cells stimulated with cytokines
311 might induce a transcriptional program enriched for asthma-associated genes. First we used a
312 bulk RNA-seq dataset consisting of human bronchial epithelial cells (HBECs) that were stimulated
313 with either IFN α , IFN γ , IL-13 or IL-17 (N = 6 healthy donors, **Figure 6A**) ⁴⁸. We selected the top
314 10% upregulated genes by t-statistic for each stimulus (**Supplementary Figure 10A**). We used
315 LDSC-SEG to analyze these 4 sets of genes in the 4 asthma-associated traits and the control traits.
316 We did not identify any significant heritability enrichment for any of the stimuli gene sets for the
317 asthma-associated traits tested here (**Figure 6B**), nor for the control traits (except for genes
318 upregulated by IFN γ for rheumatoid arthritis, **Supplementary Figure 10B**).

319

320 Next, given that IL-13 might work synergistically with IL-4, we performed bulk RNA-seq of nasal
321 airway epithelial cells from healthy donors (N = 5) co-stimulated in vitro with IL-4 and IL-13
322 (**Figure 6C**). We tested DE genes for the IL-4-IL-13 condition compared to the unstimulated
323 control. In line with the results observed in the previous analysis, we found no significant
324 enrichment for any of the asthma-associated (**Figure 6D**) or control traits (except for AD,
325 **Supplementary Figure 10E**). Together, these results suggest that epithelial cells upregulate
326 asthma-associated genes in a stimulus-specific manner, which to the extent of this study, is not
327 caused by the stimulation with the cytokines tested here.

328

329 Discussion

330 While some genetic risk variants for asthma are enriched near genes with T cell-specific
331 expression ^{13,17,22,28}, the effects of most variants on gene regulation remain unknown. In this
332 study, we asked whether some of these “missing regulatory effects” could be hidden in airway
333 epithelial cells, given they are the first line of contact for respiratory viruses, including those that
334 have been associated with asthma development or exacerbations. We analyzed ten
335 transcriptomic datasets of human airway epithelial cells cultured under different stimuli and
336 integrated them with genetic susceptibility data for asthma and related traits. We consistently
337 showed that rhinovirus-activated epithelial cells significantly upregulate genes at childhood-
338 onset asthma risk loci. We observed this in samples from healthy donors and even more so in
339 cells from asthma patients. Notably, we discovered that non-ciliated cells are the subset driving
340 these associations with asthma, indicating that non-ciliated airway epithelial cells activated with
341 rhinovirus are key mediators of genetic susceptibility to childhood-onset asthma. While other
342 respiratory viruses, such as influenza might also significantly upregulate genes at asthma risk loci,
343 this is not likely a general virus response or epithelial cell activation signature, given that we did
344 not detect asthma heritability enrichment for SARS-CoV-2 or cytokine-upregulated genes.

345

346 Our findings are consistent with epidemiological studies that have shown associations between
347 wheezing illness caused by rhinovirus infection and asthma development in children ^{4,49–51}.
348 Additionally, a previous birth cohort study identified genetic variants at the 17q21 locus that

349 were associated with asthma in children who had rhinovirus-associated wheezing illness in the
350 first 3 years of life, but not in children who had RSV-associated wheezing illnesses at those same
351 ages ⁵². In that study, rhinovirus upregulated two genes at this locus, *ORMDL3* and *GSDMB*, in
352 PBMCs ⁵². Here, we observe that in non-ciliated airway epithelial cells rhinovirus induces
353 upregulation of *GSDMB* as well as putative causal genes in 54 additional loci. This demonstrates
354 a widespread interaction between *in vitro* rhinovirus infection and polygenic susceptibility to
355 childhood-onset asthma, specifically mediated through airway epithelial cells. These findings are
356 concordant with a previous study reporting that genes at COA-specific risk loci (as compared to
357 AOA) have high expression in skin, which is a barrier tissue with an abundance of epithelial cells
358 ³⁰. Overall, our findings support the hypothesis that rhinovirus could be causally linked to asthma
359 development in children and not just be a biomarker of children destined to develop asthma. Not
360 all children that get RV-wheezing develop asthma, and our findings suggest that the combination
361 of preschool rhinovirus wheezing illnesses and a high genetic burden synergistically promote the
362 development of childhood asthma.

363
364 We discovered that non-ciliated cells (basal, secretory, and transitional) are the specific cell
365 subsets that overexpress genes at asthma risk loci. This suggests that an important fraction of
366 the non-coding risk variants for asthma likely affect gene regulation in non-ciliated cells under
367 specific viral activation states. In our study we looked at two different rhinovirus types. For the
368 case of RV-C15, the receptor of the virus, CDHR3, is mainly expressed in the ciliated cells ^{53,54} and
369 viral RNA quantification confirmed this subset is the one directly infected by the virus
370 **(Supplementary Figure 5G)**. This suggested that RV-infected ciliated cells efficiently transmit a
371 signal to the non-ciliated cells, which then express genes in asthma risk loci. The time course
372 experiments indicated this upregulation of asthma-associated genes occurred predominantly at
373 24 and 42 hours ³⁵. In our analyses of RV-A16 infected epithelial cells, the data came from bulk
374 RNA-seq of basal cells (non-ciliated) treated for 24 hours. In contrast to RV-C15, RV-A16 binds to
375 the ICAM receptor, which is expressed in ciliated cells and basal cells ⁵⁵. Strikingly, while the cell
376 subsets that get directly infected differ between the two RV strains, both significantly
377 upregulated asthma-associated genes in non-ciliated cells at 24 hours. By contrast, for SARS-CoV-

378 2, *in vitro* infection did not upregulate genes in asthma risk loci; rather, the non-infected cells
379 presented a significant expression of asthma-associated genes. Although the data in this study
380 came from only one individual, the cells with significant disease relevant scores were also
381 predominantly non-ciliated cells (> 83%, **Supplementary Fig. 9**). Future single-cell studies with
382 larger sample sizes and ascertaining infection by multiple types of viruses could point to
383 additional epithelial cell subsets and cell states as candidate drivers of genetic susceptibility to
384 asthma.

385
386 The observations in our study may also be relevant to virus-induced asthma exacerbation ⁵⁶.
387 Here, we not only demonstrate that rhinovirus infection induces a transcriptional response
388 enriched in childhood-onset asthma risk, but we also identified a heritability enrichment for
389 genes upregulated in asthma patients compared to controls, even when controlling for RV
390 infection (suggestive P = 0.051, **Figure 3E**). This result goes in line with a previous observation
391 that, at the open chromatin level, airway epithelial cells of asthma patients have a large amount
392 of open chromatin regions at baseline that are RV-response regions in healthy controls ³⁴. It is
393 possible that over-expression of asthma-associated genes at baseline may increase the risk for
394 acute virus-induced exacerbations in patients with asthma. Influenza infections, which can cause
395 asthma exacerbations (especially in adults) ⁵⁷⁻⁵⁹, induced an enrichment of both adult-onset and
396 childhood-onset asthma heritability in influenza upregulated genes in airway epithelial cells.
397 Furthermore, SARS-CoV-2 seems less likely than other viruses to provoke asthma exacerbations,
398 and asthma does not appear to be a risk factor for severe SARS-CoV-2 infection ⁶⁰. This could be
399 due to multiple reasons, such as allergy-induced reduction in the ACE2 receptor ⁶¹, but it is also
400 in line with our observations that SARS-CoV-2 infection itself does not induce a transcriptional
401 program significantly enriched in asthma heritability ⁶¹.

402
403 Our study had some limitations. We were not able to ascertain all possible epithelial cell subsets
404 and states. Most of the datasets analyzed involved *in vitro* infections, rather than *in vivo* infected
405 samples. Additionally, all samples came from adults, which made it all the more striking that we
406 detected heritability enrichments for childhood-onset asthma. Future studies in children are

407 important to validate these findings. Furthermore, we were limited by the cell sources and
408 specific time points and experimental designs of each study. In particular, the absence of asthma
409 heritability enrichment in cytokine-upregulated genes in epithelial cells could imply multiple
410 scenarios. One possibility could be that even though pro-inflammatory cytokines (IL-4, IL-13,
411 IFN α , IFN γ , IL-17) upregulate many genes in epithelial cells (684-2876 at 5% FDR in our analyses),
412 they do not significantly interact with polygenic risk factors for asthma in epithelial cells. Other
413 possibilities for the absence of signal could be that the cytokine-induced activation might interact
414 with genetic risk factors acting in T cells or other non-epithelial cells, or that there are interactions
415 with environmental conditions not present in the models included in this analysis.

416
417 Overall, our findings of asthma heritability enrichment in various epithelial cell states (resting
418 versus virus-infected, patients versus healthy controls) could reflect variability in how risk
419 variants contribute to disease onset versus progression. These results highlight the importance
420 of studying the cellular context in which GWAS loci contribute to disease risk and will ultimately
421 help to better understand the mechanisms through which those risk variants are acting.
422 Moreover, the outcomes of our study could open the door to new therapeutic avenues. Indeed,
423 drug targets that have genetic evidence are more likely to be approved and move forward to
424 clinical trials than those without it ⁶². Large-scale multi-omic studies (with comparable power to
425 GWAS ⁶³) of non-ciliated airway epithelial cells activated with rhinovirus could help identify the
426 target genes of non-coding asthma risk variants, together with functional validations with
427 approaches such as base editing. Finally, if our observations are confirmed and further
428 characterized by future studies, it would support the development of a rhinovirus vaccine or
429 other protective intervention as a way to prevent childhood-onset asthma ⁶⁴.

430 Material and methods

431 Dataset collection

432 We downloaded transcriptomic datasets from the National Center for Biotechnology Information
433 (NCBI) Gene Expression Omnibus (GEO), Genome Sequence Archive (GSA) and from ImmPORT.

434 We also downloaded a chromatin accessibility dataset (ATAC-seq) from GEO (**Supplementary**
 435 **Table 2**).

Supplementary Table 2. Datasets used in this study.		
Data type	Source	Accession number
ATAC-seq	Calderon et al., 2019	GSE118189
scRNA-seq	Wang et al., 2023	HRA000772 (Genome Sequence Archive)
scRNA-seq	Seumois et al., 2020	GSE146170
RNA-seq	Helling et al., 2020	GSE152550
RNA-seq	Basnet et al., 2023	SDY1882 (ImmPORT)
scRNA-seq	Basnet et al., 2023	SDY1882 (ImmPORT)
RNA-seq	Tao et al., 2022	GSE193164
scRNA-seq	Ravindra et al., 2021	GSE166766
RNA-seq	Koh et al., 2022	GSE185200
RNA-seq	Barret lab	Will be published as part of current study

436

437 **Ethical approval**

438 The Mass General Brigham Institutional Review Board gave ethical approval for the Barrett
 439 dataset.

440

441 **GWAS collection**

442 We downloaded pre-processed summary statistics for the four asthma-associated traits; adult-
 443 onset asthma, childhood-onset asthma, all asthma, allergy/eczema and for those in our control
 444 panel; height, Alzheimer’s disease and rheumatoid arthritis (**Supplementary Table 1**).

445

Supplementary Table 1. Summary statistics used for heritability enrichment analysis.		
	Studied trait	Reference
Asthma-associated traits	Adult-onset asthma	Ferreira et al., Am J Hum Genet, 2019 ³⁸
	Childhood-onset asthma	Ferreira et al., Am J Hum Genet, 2019 ³⁸
	Allergy/eczema	UK biobank ⁶⁵
	All asthma	UK biobank ⁶⁵
Control traits	Height	Lango, et al., Nature, 2010 ⁶⁶

	Alzheimer's disease	Lambert, et al., Nat Genet, 2013 ⁶⁷
	Rheumatoid arthritis	Okada, et al., Nature, 2014 ⁶⁸

446

447 **Summary statistics processing for visualization**

448 We downloaded the childhood-onset asthma and adult-onset asthma³⁸ summary statistics from
449 the GWAS catalog. We used the harmonized summary statistics in the GRCh38 version of the
450 genome. We removed the MHC region (chr6:28510120-33480577).

451

452 **Bulk RNA-seq data processing and quality check**

453 FASTQ files were aligned to the GRCh38 or GRCh37 human genome using STAR (v2.7.9a) with
454 standard parameters and two-pass mode, or the Salmon tool (v1.5.1). For BAM files generated
455 with STAR, counts were calculated using RSEM (v1.3.3). We normalized the counts by
456 transforming them to their $\log_2(\text{TPM}+1)$ value, where TPM stands for transcripts per million. To
457 detect outlier samples, we performed principal component analysis on scaled normalized
458 expression for the top 1000 most variable genes that were expressed in at least 25% of the
459 samples. For alignment and quantification, we used the ENSEMBL reference annotation release
460 105 which was downloaded from the ENSEMBL website.

461

462 **Differential expression analyses**

463 Differential gene expression was tested using a linear mixed model, similar to what we did in
464 Gutierrez-Arcelus et al.⁶⁹. Specifically, we used a likelihood ratio test between two nested models
465 (*anova* function in R). In these models, gene expression levels ($\log_2(\text{TPM} + 1)$) represent the
466 dependent variable. "Donor ID" was included as a predictor variable, treated as a random effect.
467 To compare one condition against the others, we indicated with 1 the tested condition and 0 for
468 the others (the test variable). We used the function "lmer" from the R package "lme4" to
469 implement the model. For risk gene visualization in the miami plot, P-values were corrected for
470 multiple hypothesis testing using the package "qvalue". Differentially expressed genes at 5% FDR
471 are reported for depicting specific genes in risk loci. After each analysis, we calculated a t-statistic
472 for each gene to rank them and chose the top 10% as annotations for heritability enrichment

473 analysis (see LDSC-SEG section below). The details of each analysis are divided by dataset and
474 described in the following section.

475

476 - *Helling Dataset*

477 To assess DE genes between rhinovirus treatment and PBS vehicle control within healthy
478 individuals, we tested genes that had a normalized count greater than 1 in at least 9 samples
479 which led to a total of 14,883 genes. The threshold for the minimum number of samples reflected
480 half of the biological replicates (9/18). In addition to having “donor ID” as a random effect, we
481 accounted for “sex” as a fixed effect. We repeated this process in asthma patients only, testing
482 14,888 genes for differential expression between rhinovirus infection and PBS vehicle control. To
483 find DE genes from asthma patients compared to healthy controls, we took all the samples and
484 recalculated the number of genes present in at least 9 samples. We tested 15,935 genes and
485 incorporated “treatment” with either PBS or rhinovirus as a fixed effect covariate in the model,
486 and tested for disease status (0/1).

487

488 *Tao Dataset*

489 We included 16,031 genes having a normalized count greater than 1 in half of the samples (3/6
490 samples). We tested for differential expression between influenza treatment and control (sham).

491

492 *Koh Dataset*

493 We tested 14,988 genes, to find differentially expressed genes specific to each condition
494 compared to all others: IFN α , IFN γ , IL-13, and IL-17, respectively. We selected genes having a
495 normalized count greater than 1 in at least 6 samples. This number reflected the smallest amount
496 of replicates found across conditions (6/36 samples).

497

498 - *Basnet Dataset*

499 We excluded the resting sample from donor B03 from these analyses (see Methods, Bulk RNA-
500 seq, QC, and analysis). To obtain differentially expressed gene profiles for each time point, we
501 performed four separate models in which we tested a single time point against the other two

502 and the resting condition. Our fourth model tested for DE genes in activation conditions versus
503 the resting state through the same approach. Since we had 3 biological replicates for most time
504 points, we tested genes with a normalized count greater than 1 in at least (3/11) samples, which
505 yielded 14,380 genes. This gene set was used for all models.

506

507 - *Barrett Dataset*

508 Air-liquid interface (ALI) cultures were grown from nasal basal epithelial cells from 6 healthy adult
509 donors. ALIs were allowed to mature for 14 days, then stimulated with 10 ng/mL of IL-4 and 10
510 ng/mL of IL-13 for an additional 7 days, and then lysed with TCL buffer (Qiagen 1031576) at the
511 conclusion of the experiment. Lysates were stored at -80C and later submitted to the Broad for
512 SmartSeq2 low input bulk RNA-seq (38bp paired-end sequencing).

513

514 To obtain genes DE under IL-4 and IL-13 co-stimulation we compared them against the non-
515 stimulated cells. We tested 13,518 genes that had a normalized count greater than 1 in at least
516 half of the samples (9/18) samples.

517

518 **ATAC-seq data processing and differential accessibility analysis**

519 We used the 829,942 consensus peaks called by Calderon et al. (peaks were called in each sample
520 separately, then merged across samples, and then counts were re-calculated for all samples using
521 the merged peak coordinates). We transformed counts into reads per kilobase per million
522 (RPKM), then quantile normalized and finally scaled to their $\log_2(\text{normalized RPKM}+1)$. To assess
523 differentially accessible (DA) peaks, we first calculated the mean normalized count per cell type
524 and then created cell-type accessible sets of peaks. We included a peak in the set if it had a
525 normalized count greater than the mean of the cell type in at least half of the samples
526 corresponding to subtypes of that cell type. We tested between 400 and 600 thousand peaks per
527 cell-type for DA. To do so, we implemented a linear mixed model using the normalized counts as
528 the response variable, and for the predictor, a bit flag system indicating 1 if the sample belonged
529 to the tested cell type and 0 for the remaining cells. Peaks were sorted by t-statistic and we took
530 the top 10% peaks for each cell-type-specific annotation. This process was replicated for a second
531 selection model, implemented to divide peaks between stimulated and unstimulated categories.

532

533 **Single-cell RNA-seq, QC and analysis**

534 FASTQ files from the single-cell RNA-seq dataset from Wang et al., Seumois et al., Basnet et al.,
535 and Ravindra et al.,^{35,70–72} were downloaded as indicated in the “Dataset Collection” section. For
536 each dataset, we aligned FASTQ files to the human reference human genome GRCh38⁷³, using
537 the GENCODE release 32 with cellranger count (v6.1.2), using default parameters. For Basnet et
538 al, we added the RV-C15 sequence to the reference genome. Counts were then aggregated using
539 the cellranger aggr (v6.1.2) function with the default parameters. The subsequent analyses were
540 done for each of the datasets individually. We discarded cells with less than 500 genes expressed
541 and cells expressing more than 20% of mitochondrial genes. We normalized raw counts with the
542 “LogNormalize” method from Seurat package (v4.0.5). We used the normalized counts to
543 perform a PCA with the 1000 most variable genes. We used the top 20 principal components to
544 perform dimensionality reduction with UMAP to visualize the data. We identified clusters using
545 the “FindClusters” function with the Louvain algorithm and a resolution parameter of 0.2, using
546 the top 20 principal components (PCs). We corrected PCs with Harmony package⁷⁴ (v0.1.1) as
547 indicated as follows, if nothing is indicated, no corrections were applied. For Wang et al., dataset
548 we corrected for “donor ID” and “tissue”. For Basnet et al., dataset we corrected for “donor ID”
549 and virus infection. For Ravindra et al., dataset we corrected for virus infection.

550 To identify which cellular type was present in each cell cluster, we used the function
551 “FindVariableFeatures” (parameter; test.use=wilcox) from Seurat package to identify
552 differentially expressed genes in each cluster. If immune cells were present in the dataset we
553 used the tool MCPcounter (v1.2.0) to annotate immune cells⁷⁵. Based on these cellular markers
554 we annotated the clusters with data from the literature^{35,76,77}.

555 For data from Ziegler et al.⁴⁰ we used the UMAP coordinates, and the cell annotation originally
556 published by the authors.

557 **LDSC-SEG**

558 State-specific gene sets were generated using the top 10% of the genes tested ranked by t-
559 statistic for each of our DE analyses. Genes coordinates were mapped from the human genome

560 reference GRCh37 GTF file and formatted into bed files. We repeated this process to generate
561 control bed files containing all the genes tested for DE in each analysis. Symmetric windows of
562 100kb were added at each side of the genes using the bedtools (v2.31) “slop” function. For bed
563 files containing ATAC-seq peaks, this window consisted of 225 bp at each side of the peak, to
564 represent a similar genomic coverage. LD-Score files were generated using the LDSC pipeline
565 along with data from HapMap 3 and Phase 3 of the European 1000 Genomes obtained from the
566 LDSC-repository. The regression was run using the baseline model v1.2. We reported the P values
567 of regression coefficients, and normalized regression coefficient as per-standardized-annotation
568 effect sizes τ^* as in (Gazal et al. 2017 Nat Genet)⁷⁸ to allow for multi-trait comparisons.
569 Regression P values were corrected using the “p.adjust” function from R using both FDR and
570 bonferroni methods. The reference GTF file used to map the genes was obtained from GENCODE
571 (v37).

572

573 **MAGMA and scDRS**

574 We used the adult-onset asthma, the childhood-onset asthma, the allergy/eczema, the all-
575 asthma, the rheumatoid arthritis, and the Alzheimer’s GWAS summary statistics as well as the
576 corresponding set of 1000 putative disease genes (obtained with MAGMA) provided in the
577 original publication of the scDRS method^{17,79}.

578 We used MAGMA (v1.10) to compute the gene-level association P-values and z-scores from
579 GWAS summary statistics of Height. We transformed P-values to z-scores using this formula:
580 $2 * pnorm(abs(zscore), mean = 0, sd = 1, lower.tail = F)$ in R. To map SNPs to genes, we used magma
581 with default parameters specified in the scDRS documentation. We retrieved the top 1000 genes
582 based on MAGMA z-score as putative disease genes.

583

584 We used scDRS (v1.0.2) to quantify the expression of the putative disease genes derived from
585 GWAS summary statistics using MAGMA in each cell of each single-cell RNA-seq dataset
586 separately for the 8 GWAS tested and described previously (Table dataset). We used the function
587 scDRS “compute-score” with default parameters (--flag-filter-data False).

588

589 **Cell-cell interaction between ciliated epithelial cells and non-ciliated epithelial cells**

590 To identify potential pairs of interactors between ciliated and non-ciliated epithelial cells we used
591 the dataset of Basnet et al. ³⁵. We first evaluated which genes were differentially expressed
592 between rhinovirus infected epithelial cells and non-ciliated non-infected epithelial cells. We
593 identified the hypothetical pair of interactors (ligand-receptor) between ciliated and non-ciliated
594 cells with CellPhoneDB (v3.1.0) with the method “deg_analysis”, using the list of differentially
595 expressed genes defined before and the default parameter. We filtered the results by identifying
596 the ligand being expressed in ciliated cells and a receptor expressed in non-ciliated cells.

597

598 **Linking variants to genes**

599 For the Miami plot we used three different and complementary approaches to map variants to
600 genes. First, we used data from Open Target Genetics website ⁸⁰. We queried the website to
601 retrieve information for childhood-onset asthma (GCST007995) and adult-onset asthma
602 (GCST007799). We then extracted the L2G gene and the Closest Gene for each variant when
603 information was available. We also added a window of 250kb around each variant with the
604 “bedtools slop” function and retrieved the genes falling in those regions with the “bedtools
605 intersect” function. Finally, we obtained the intersect between this “snp-to-gene” list of genes
606 and the genes upregulated upon rhinovirus infection (genes annotated on **Figure 4A**).

607

608 We also retrieved the lead variants from the original paper from Ferreira et al. ³⁸. We added a
609 window of 250kb around each variant with the “bedtools slop” function and retrieved the genes
610 falling in those regions with the “bedtools intersect” function. We identified the closest gene to
611 the variant by using the function “bedclosest”.

612

613 **Software description (Plots, R, and Biorender)**

614 All the plots were generated with R and graphic schematics were generated with Biorender.

615

616 **Data availability**

617 Bulk RNA-seq data on dataset with IL-4 and IL-13 activation of airway epithelial cells will be made
618 available in GEO and dbGAP. Other datasets used are publicly available (details in **Supplementary**
619 **Table 1**).

620 Acknowledgements

621 This study was supported by U19AI095219. CO was supported by U19AI162310. NAB was
622 supported by AI134989 and U19AI095219. JG and NAB were supported by AACRC RNA
623 Sequencing Core for Airway Epithelial Cells. MGA was supported by P30AR070253. We thank
624 Donata Vercelli, Luis Barrera, Peter Nigrovic and his laboratory, and the Gutierrez-Arcelus
625 laboratory for feedback on this study.

626 Conflict of Interest Statement

627 JAB has served on scientific advisory boards for Siolta Therapeutics, Third Harmonic Bio,
628 Sanofi/Aventis. NAB has served on scientific advisory boards for Regeneron. The rest of the
629 authors declare that they have no relevant conflicts of interest.

630

631 References

632

- 633 1. Porsbjerg, C., Melén, E., Lehtimäki, L., and Shaw, D. (2023). Asthma. *Lancet* *401*, 858–873.
- 634 2. Heijink, I.H., Kuchibhotla, V.N.S., Roffel, M.P., Maes, T., Knight, D.A., Sayers, I., and Nawijn, M.C.
635 (2020). Epithelial cell dysfunction, a major driver of asthma development. *Allergy* *75*, 1902–1917.
- 636 3. Hellings, P.W., and Steelant, B. (2020). Epithelial barriers in allergy and asthma. *J. Allergy Clin.*
637 *Immunol.* *145*, 1499–1509.
- 638 4. Jackson, D.J., and Gern, J.E. (2022). Rhinovirus Infections and Their Roles in Asthma: Etiology and
639 Exacerbations. *J. Allergy Clin. Immunol. Pract.* *10*, 673–681.
- 640 5. Holgate, S.T., Wenzel, S., Postma, D.S., Weiss, S.T., Renz, H., and Sly, P.D. (2015). Asthma. *Nat Rev*
641 *Dis Primers* *1*, 15025.
- 642 6. Loxham, M., and Davies, D.E. (2017). Phenotypic and genetic aspects of epithelial barrier function
643 in asthmatic patients. *J. Allergy Clin. Immunol.* *139*, 1736–1751.
- 644 7. Kim, K.W., and Ober, C. (2019). Lessons Learned From GWAS of Asthma. *Allergy Asthma Immunol.*
645 *Res.* *11*, 170–187.

- 646 8. Vicente, C.T., Revez, J.A., and Ferreira, M.A.R. (2017). Lessons from ten years of genome-wide
647 association studies of asthma. *Clin Transl Immunology* 6, e165.
- 648 9. Banerjee, S., Webber, C., and Poole, A.R. (1992). The induction of arthritis in mice by the cartilage
649 proteoglycan aggrecan: roles of CD4+ and CD8+ T cells. *Cell. Immunol.* 144, 347–357.
- 650 10. Kobezda, T., Ghassemi-Nejad, S., Mikecz, K., Glant, T.T., and Szekanecz, Z. (2014). Of mice and men:
651 how animal models advance our understanding of T-cell function in RA. *Nat. Rev. Rheumatol.* 10,
652 160–170.
- 653 11. Trynka, G., Sandor, C., Han, B., Xu, H., Stranger, B.E., Liu, X.S., and Raychaudhuri, S. (2013).
654 Chromatin marks identify critical cell types for fine mapping complex trait variants. *Nat. Genet.* 45,
655 124–130.
- 656 12. Finucane, H.K., Bulik-Sullivan, B., Gusev, A., Trynka, G., Reshef, Y., Loh, P.-R., Anttila, V., Xu, H.,
657 Zang, C., Farh, K., et al. (2015). Partitioning heritability by functional annotation using genome-
658 wide association summary statistics. *Nat. Genet.* 47, 1228–1235.
- 659 13. Finucane, H.K., Reshef, Y.A., Anttila, V., Slowikowski, K., Gusev, A., Byrnes, A., Gazal, S., Loh, P.-R.,
660 Lareau, C., Shores, N., et al. (2018). Heritability enrichment of specifically expressed genes
661 identifies disease-relevant tissues and cell types. *Nat. Genet.* 50, 621–629.
- 662 14. Gjoneska, E., Pfenning, A.R., Mathys, H., Quon, G., Kundaje, A., Tsai, L.-H., and Kellis, M. (2015).
663 Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease.
664 *Nature* 518, 365–369.
- 665 15. Bettcher, B.M., Tansey, M.G., Dorothée, G., and Heneka, M.T. (2021). Peripheral and central
666 immune system crosstalk in Alzheimer disease - a research prospectus. *Nat. Rev. Neurol.* 17, 689–
667 701.
- 668 16. Calderon, D., Nguyen, M.L.T., Mezger, A., Kathiria, A., Müller, F., Nguyen, V., Lescano, N., Wu, B.,
669 Trombetta, J., Ribado, J.V., et al. (2019). Landscape of stimulation-responsive chromatin across
670 diverse human immune cells. *Nat. Genet.* 51, 1494–1505.
- 671 17. Zhang, M.J., Hou, K., Dey, K.K., Sakaue, S., Jagadeesh, K.A., Weinand, K., Taychameekitchai, A.,
672 Rao, P., Pisco, A.O., Zou, J., et al. (2022). Polygenic enrichment distinguishes disease associations of
673 individual cells in single-cell RNA-seq data. *Nat. Genet.*, 1–9.
- 674 18. Robinson, D.S., Hamid, Q., Ying, S., Tscopoulos, A., Barkans, J., Bentley, A.M., Corrigan, C., Durham,
675 S.R., and Kay, A.B. (1992). Predominant TH2-like bronchoalveolar T-lymphocyte population in
676 atopic asthma. *N. Engl. J. Med.* 326, 298–304.
- 677 19. Fahy, J.V. (2015). Type 2 inflammation in asthma--present in most, absent in many. *Nat. Rev.*
678 *Immunol.* 15, 57–65.
- 679 20. Augustine, T., Al-Aghbar, M.A., Al-Kowari, M., Espino-Guarch, M., and van Panhuys, N. (2022).
680 Asthma and the Missing Heritability Problem: Necessity for Multiomics Approaches in Determining
681 Accurate Risk Profiles. *Front. Immunol.* 13, 822324.

- 682 21. Busse, W.W., and Viswanathan, R. (2022). What has been learned by cytokine targeting of asthma?
683 *J. Allergy Clin. Immunol.* *150*, 235–249.
- 684 22. Mu, Z., Wei, W., Fair, B., Miao, J., Zhu, P., and Li, Y.I. (2021). The impact of cell type and context-
685 dependent regulatory variants on human immune traits. *Genome Biol.* *22*, 122.
- 686 23. Chun, S., Casparino, A., Patsopoulos, N.A., Croteau-Chonka, D.C., Raby, B.A., De Jager, P.L.,
687 Sunyaev, S.R., and Cotsapas, C. (2017). Limited statistical evidence for shared genetic effects of
688 eQTLs and autoimmune-disease-associated loci in three major immune-cell types. *Nat. Genet.* *49*,
689 600–605.
- 690 24. GTEx Consortium, Laboratory, Data Analysis & Coordinating Center (LDACC)—Analysis Working
691 Group, Statistical Methods groups—Analysis Working Group, Enhancing GTEx (eGTEx) groups, NIH
692 Common Fund, NIH/NCI, NIH/NHGRI, NIH/NIMH, NIH/NIDA, Biospecimen Collection Source Site—
693 NDRI, et al. (2017). Genetic effects on gene expression across human tissues. *Nature* *550*, 204–213.
- 694 25. Gutierrez-Arcelus, M., Baglaenko, Y., Arora, J., Hannes, S., Luo, Y., Amariuta, T., Teslovich, N., Rao,
695 D.A., Ermann, J., Jonsson, A.H., et al. (2020). Allele-specific expression changes dynamically during
696 T cell activation in HLA and other autoimmune loci. *Nat. Genet.* *52*, 247–253.
- 697 26. Elorbany, R., Popp, J.M., Rhodes, K., Strober, B.J., Barr, K., Qi, G., Gilad, Y., and Battle, A. (2022).
698 Single-cell sequencing reveals lineage-specific dynamic genetic regulation of gene expression
699 during human cardiomyocyte differentiation. *PLoS Genet.* *18*, e1009666.
- 700 27. Umans, B.D., Battle, A., and Gilad, Y. (2021). Where Are the Disease-Associated eQTLs? *Trends*
701 *Genet.* *37*, 109–124.
- 702 28. Soskic, B., Cano-Gamez, E., Smyth, D.J., Ambridge, K., Ke, Z., Matte, J.C., Bossini-Castillo, L.,
703 Kaplanis, J., Ramirez-Navarro, L., Lorenc, A., et al. (2022). Immune disease risk variants regulate
704 gene expression dynamics during CD4+ T cell activation. *Nat. Genet.* *54*, 817–826.
- 705 29. Soskic, B., Cano-Gamez, E., Smyth, D.J., Rowan, W.C., Nakic, N., Esparza-Gordillo, J., Bossini-Castillo,
706 L., Tough, D.F., Larminie, C.G.C., Bronson, P.G., et al. (2019). Chromatin activity at GWAS loci
707 identifies T cell states driving complex immune diseases. *Nat. Genet.* *51*, 1486–1493.
- 708 30. Pividori, M., Schoettler, N., Nicolae, D.L., Ober, C., and Im, H.K. (2019). Shared and distinct genetic
709 risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide
710 studies. *Lancet Respir Med* *7*, 509–522.
- 711 31. Zhu, Z., Lee, P.H., Chaffin, M.D., Chung, W., Loh, P.-R., Lu, Q., Christiani, D.C., and Liang, L. (2018). A
712 genome-wide cross-trait analysis from UK Biobank highlights the shared genetic architecture of
713 asthma and allergic diseases. *Nat. Genet.* *50*, 857–864.
- 714 32. Guibas, G.V., Mathioudakis, A.G., Tsoumani, M., and Tsabouri, S. (2017). Relationship of Allergy
715 with Asthma: There Are More Than the Allergy “Eggs” in the Asthma “Basket.” *Front Pediatr* *5*, 92.
- 716 33. Khan, A.H., Gouia, I., Kamat, S., Johnson, R., Small, M., and Siddall, J. (2023). Prevalence and
717 Severity Distribution of Type 2 Inflammation-Related Comorbidities Among Patients with Asthma,
718 Chronic Rhinosinusitis with Nasal Polyps, and Atopic Dermatitis. *Lung* *201*, 57–63.

- 719 34. Helling, B.A., Sobreira, D.R., Hansen, G.T., Sakabe, N.J., Luo, K., Billstrand, C., Laxman, B., Nicolae,
720 R.I., Nicolae, D.L., Bochkov, Y.A., et al. (2020). Altered transcriptional and chromatin responses to
721 rhinovirus in bronchial epithelial cells from adults with asthma. *Commun Biol* 3, 678.
- 722 35. Basnet, S., Mohanty, C., Bochkov, Y.A., Brockman-Schneider, R.A., Kendzioriski, C., and Gern, J.E.
723 (2023). Rhinovirus C Causes Heterogeneous Infection and Gene Expression in Airway Epithelial Cell
724 Subsets. *Mucosal Immunol.* 10.1016/j.mucimm.2023.01.008.
- 725 36. Bochkov, Y.A., Watters, K., Ashraf, S., Griggs, T.F., Devries, M.K., Jackson, D.J., Palmenberg, A.C.,
726 and Gern, J.E. (2015). Cadherin-related family member 3, a childhood asthma susceptibility gene
727 product, mediates rhinovirus C binding and replication. *Proc. Natl. Acad. Sci. U. S. A.* 112, 5485–
728 5490.
- 729 37. Efremova, M., Vento-Tormo, M., Teichmann, S.A., and Vento-Tormo, R. (2020). CellPhoneDB:
730 inferring cell-cell communication from combined expression of multi-subunit ligand-receptor
731 complexes. *Nat. Protoc.* 15, 1484–1506.
- 732 38. Ferreira, M.A.R., Mathur, R., Vonk, J.M., Szwajda, A., Brumpton, B., Granell, R., Brew, B.K., Ullemar,
733 V., Lu, Y., Jiang, Y., et al. (2019). Genetic Architectures of Childhood- and Adult-Onset Asthma Are
734 Partly Distinct. *Am. J. Hum. Genet.* 104, 665–684.
- 735 39. Esparza-Gordillo, J., Weidinger, S., Fölster-Holst, R., Bauerfeind, A., Ruschendorf, F., Patone, G.,
736 Rohde, K., Marenholz, I., Schulz, F., Kerscher, T., et al. (2009). A common variant on chromosome
737 11q13 is associated with atopic dermatitis. *Nat. Genet.* 41, 596–601.
- 738 40. Ziegler, C.G.K., Miao, V.N., Owings, A.H., Navia, A.W., Tang, Y., Bromley, J.D., Lotfy, P., Sloan, M.,
739 Laird, H., Williams, H.B., et al. (2021). Impaired local intrinsic immunity to SARS-CoV-2 infection in
740 severe COVID-19. *Cell* 184, 4713-4733.e22.
- 741 41. Lambrecht, B.N., Hammad, H., and Fahy, J.V. (2019). The Cytokines of Asthma. *Immunity* 50, 975–
742 991.
- 743 42. Hammad, H., and Lambrecht, B.N. (2021). The basic immunology of asthma. *Cell* 184, 1469–1485.
- 744 43. Camiolo, M.J., Zhou, X., Oriss, T.B., Yan, Q., Gorry, M., Horne, W., Trudeau, J.B., Scholl, K., Chen, W.,
745 Kolls, J.K., et al. (2021). High-dimensional profiling clusters asthma severity by lymphoid and non-
746 lymphoid status. *Cell Rep.* 35, 108974.
- 747 44. Woodruff, P.G., Boushey, H.A., Dolganov, G.M., Barker, C.S., Yang, Y.H., Donnelly, S., Ellwanger, A.,
748 Sidhu, S.S., Dao-Pick, T.P., Pantoja, C., et al. (2007). Genome-wide profiling identifies epithelial cell
749 genes associated with asthma and with treatment response to corticosteroids. *Proc. Natl. Acad.*
750 *Sci. U. S. A.* 104, 15858–15863.
- 751 45. Woodruff, P.G., Modrek, B., Choy, D.F., Jia, G., Abbas, A.R., Ellwanger, A., Koth, L.L., Arron, J.R., and
752 Fahy, J.V. (2009). T-helper type 2-driven inflammation defines major subphenotypes of asthma.
753 *Am. J. Respir. Crit. Care Med.* 180, 388–395.
- 754 46. Krishnamoorthy, N., Douda, D.N., Brüggemann, T.R., Ricklefs, I., Duvall, M.G., Abdulnour, R.-E.E.,
755 Martinod, K., Tavares, L., Wang, X., Cernadas, M., et al. (2018). Neutrophil cytoplasmic granules induce TH17

- 756 differentiation and skew inflammation toward neutrophilia in severe asthma. *Sci Immunol* 3.
757 10.1126/sciimmunol.aao4747.
- 758 47. Castro, M., Corren, J., Pavord, I.D., Maspero, J., Wenzel, S., Rabe, K.F., Busse, W.W., Ford, L., Sher,
759 L., FitzGerald, J.M., et al. (2018). Dupilumab Efficacy and Safety in Moderate-to-Severe
760 Uncontrolled Asthma. *N. Engl. J. Med.* 378, 2486–2496.
- 761 48. Koh, K.D., Bonser, L.R., Eckalbar, W.L., Yizhar-Barnea, O., Shen, J., Zeng, X., Hargett, K.L., Sun, D.I.,
762 Zlock, L.T., Finkbeiner, W.E., et al. (2023). Genomic characterization and therapeutic utilization of
763 IL-13-responsive sequences in asthma. *Cell Genom* 3, 100229.
- 764 49. Rubner, F.J., Jackson, D.J., Evans, M.D., Gangnon, R.E., Tisler, C.J., Pappas, T.E., Gern, J.E., and
765 Lemanske, R.F., Jr (2017). Early life rhinovirus wheezing, allergic sensitization, and asthma risk at
766 adolescence. *J. Allergy Clin. Immunol.* 139, 501–507.
- 767 50. Jarthi, T., and Gern, J.E. (2011). Rhinovirus-associated wheeze during infancy and asthma
768 development. *Curr. Respir. Med. Rev.* 7, 160–166.
- 769 51. Bønnelykke, K., Sleiman, P., Nielsen, K., Kreiner-Møller, E., Mercader, J.M., Belgrave, D., den
770 Dekker, H.T., Husby, A., Sevelsted, A., Faura-Tellez, G., et al. (2013). A genome-wide association
771 study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe
772 exacerbations. *Nat. Genet.* 46, 51–55.
- 773 52. Caliskan, M., Bochkov, Y.A., Kreiner-Møller, E., Bønnelykke, K., Stein, M.M., Du, G., Bisgaard, H.,
774 Jackson, D.J., Gern, J.E., Lemanske, R.F., Jr, et al. (2013). Rhinovirus wheezing illness and genetic
775 risk of childhood-onset asthma. *N. Engl. J. Med.* 368, 1398–1407.
- 776 53. Basnet, S., Bochkov, Y.A., Brockman-Schneider, R.A., Kuipers, I., Aesif, S.W., Jackson, D.J.,
777 Lemanske, R.F., Jr, Ober, C., Palmenberg, A.C., and Gern, J.E. (2019). CDHR3 Asthma-Risk Genotype
778 Affects Susceptibility of Airway Epithelium to Rhinovirus C Infections. *Am. J. Respir. Cell Mol. Biol.*
779 61, 450–458.
- 780 54. Griggs, T.F., Bochkov, Y.A., Basnet, S., Pasic, T.R., Brockman-Schneider, R.A., Palmenberg, A.C., and
781 Gern, J.E. (2017). Rhinovirus C targets ciliated airway epithelial cells. *Respir. Res.* 18, 84.
- 782 55. Zhou, X., Zhu, L., Lizarraga, R., and Chen, Y. (2017). Human Airway Epithelial Cells Direct Significant
783 Rhinovirus Replication in Monocytic Cells by Enhancing ICAM1 Expression. *Am. J. Respir. Cell Mol.*
784 *Biol.* 57, 216–225.
- 785 56. Hammond, C., Kurten, M., and Kennedy, J.L. (2015). Rhinovirus and asthma: a storied history of
786 incompatibility. *Curr. Allergy Asthma Rep.* 15, 502.
- 787 57. Veerapandian, R., Snyder, J.D., and Samarasinghe, A.E. (2018). Influenza in Asthmatics: For Better
788 or for Worse? *Front. Immunol.* 9, 1843.
- 789 58. Hasegawa, S., Hirano, R., Hashimoto, K., Haneda, Y., Shirabe, K., and Ichiyama, T. (2011).
790 Characteristics of atopic children with pandemic H1N1 influenza viral infection: pandemic H1N1
791 influenza reveals “occult” asthma of childhood. *Pediatr. Allergy Immunol.* 22, e119-23.

- 792 59. Obuchi, M., Adachi, Y., Takizawa, T., and Sata, T. (2013). Influenza A(H1N1)pdm09 virus and
793 asthma. *Front. Microbiol.* 4, 307.
- 794 60. Sunjaya, A.P., Allida, S.M., Di Tanna, G.L., and Jenkins, C. (2022). Asthma and risk of infection,
795 hospitalization, ICU admission and mortality from COVID-19: Systematic review and meta-analysis.
796 *J. Asthma* 59, 866–879.
- 797 61. Jackson, D.J., Busse, W.W., Bacharier, L.B., Kattan, M., O'Connor, G.T., Wood, R.A., Visness, C.M.,
798 Durham, S.R., Larson, D., Esnault, S., et al. (2020). Association of respiratory allergy, asthma, and
799 expression of the SARS-CoV-2 receptor ACE2. *J. Allergy Clin. Immunol.* 146, 203-206.e3.
- 800 62. Ochoa, D., Karim, M., Ghousaini, M., Hulcoop, D.G., McDonagh, E.M., and Dunham, I. (2022).
801 Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. *Nat. Rev. Drug*
802 *Discov.* 21, 551.
- 803 63. Mostafavi, H., Spence, J.P., Naqvi, S., and Pritchard, J.K. (2023). Systematic differences in discovery
804 of genetic effects on gene expression and complex traits. *Nat. Genet.* 55, 1866–1875.
- 805 64. Stone, C.A., Jr, and Miller, E.K. (2016). Understanding the Association of Human Rhinovirus with
806 Asthma. *Clin. Vaccine Immunol.* 23, 6–10.
- 807 65. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J.,
808 Landray, M., et al. (2015). UK biobank: an open access resource for identifying the causes of a wide
809 range of complex diseases of middle and old age. *PLoS Med.* 12, e1001779.
- 810 66. Lango Allen, H., Estrada, K., Lettre, G., Berndt, S.I., Weedon, M.N., Rivadeneira, F., Willer, C.J.,
811 Jackson, A.U., Vedantam, S., Raychaudhuri, S., et al. (2010). Hundreds of variants clustered in
812 genomic loci and biological pathways affect human height. *Nature* 467, 832–838.
- 813 67. Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., DeStafano, A.L.,
814 Bis, J.C., Beecham, G.W., Grenier-Boley, B., et al. (2013). Meta-analysis of 74,046 individuals
815 identifies 11 new susceptibility loci for Alzheimer's disease. *Nat. Genet.* 45, 1452–1458.
- 816 68. Okada, Y., Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., Kochi, Y., Ohmura, K., Suzuki, A., Yoshida,
817 S., et al. (2014). Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature*
818 506, 376–381.
- 819 69. Gutierrez-Arcelus, M., Teslovich, N., Mola, A.R., Polidoro, R.B., Nathan, A., Kim, H., Hannes, S.,
820 Slowikowski, K., Watts, G.F.M., Korsunsky, I., et al. (2019). Lymphocyte innateness defined by
821 transcriptional states reflects a balance between proliferation and effector functions. *Nat.*
822 *Commun.* 10, 687.
- 823 70. Wang, W., Xu, Y., Wang, L., Zhu, Z., Aodeng, S., Chen, H., Cai, M., Huang, Z., Han, J., Wang, L., et al.
824 (2022). Single-cell profiling identifies mechanisms of inflammatory heterogeneity in chronic
825 rhinosinusitis. *Nat. Immunol.* 23, 1484–1494.
- 826 71. Seumois, G., Ramírez-Suástegui, C., Schmiedel, B.J., Liang, S., Peters, B., Sette, A., and Vijayanand,
827 P. (2020). Single-cell transcriptomic analysis of allergen-specific T cells in allergy and asthma. *Sci*
828 *Immunol* 5. 10.1126/sciimmunol.aba6087.

- 829 72. Ravindra, N.G., Alfajaro, M.M., Gasque, V., Huston, N.C., Wan, H., Szigeti-Buck, K., Yasumoto, Y.,
830 Greaney, A.M., Habet, V., Chow, R.D., et al. (2021). Single-cell longitudinal analysis of SARS-CoV-2
831 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell
832 state changes. *PLoS Biol.* *19*, e3001143.
- 833 73. Frankish, A., Diekhans, M., Ferreira, A.-M., Johnson, R., Jungreis, I., Loveland, J., Mudge, J.M., Sisu,
834 C., Wright, J., Armstrong, J., et al. (2019). GENCODE reference annotation for the human and
835 mouse genomes. *Nucleic Acids Res.* *47*, D766–D773.
- 836 74. Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M.,
837 Loh, P.-R., and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-cell data
838 with Harmony. *Nat. Methods* *16*, 1289–1296.
- 839 75. Becht, E., Giraldo, N.A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P.,
840 Sautès-Fridman, C., Fridman, W.H., et al. (2016). Estimating the population abundance of tissue-
841 infiltrating immune and stromal cell populations using gene expression. *Genome Biol.* *17*, 218.
- 842 76. Hewitt, R.J., and Lloyd, C.M. (2021). Regulation of immune responses by the airway epithelial cell
843 landscape. *Nat. Rev. Immunol.* *21*, 347–362.
- 844 77. Ordovas-Montanes, J., Dwyer, D.F., Nyquist, S.K., Buchheit, K.M., Vukovic, M., Deb, C., Wadsworth,
845 M.H., 2nd, Hughes, T.K., Kazer, S.W., Yoshimoto, E., et al. (2018). Allergic inflammatory memory in
846 human respiratory epithelial progenitor cells. *Nature* *560*, 649–654.
- 847 78. Gazal, S., Finucane, H.K., Furlotte, N.A., Loh, P.-R., Palamara, P.F., Liu, X., Schoech, A., Bulik-Sullivan,
848 B., Neale, B.M., Gusev, A., et al. (2017). Linkage disequilibrium–dependent architecture of human
849 complex traits shows action of negative selection. *Nat. Genet.* *49*, 1421–1427.
- 850 79. de Leeuw, C.A., Mooij, J.M., Heskes, T., and Posthuma, D. (2015). MAGMA: generalized gene-set
851 analysis of GWAS data. *PLoS Comput. Biol.* *11*, e1004219.
- 852 80. Ghousaini, M., Mountjoy, E., Carmona, M., Peat, G., Schmidt, E.M., Hercules, A., Fumis, L.,
853 Miranda, A., Carvalho-Silva, D., Buniello, A., et al. (2021). Open Targets Genetics: systematic
854 identification of trait-associated genes using large-scale genetics and functional genomics. *Nucleic
855 Acids Res.* *49*, D1311–D1320.

Graphical abstract




Figure 1




Figure 1. Bronchial epithelial cells infected with rhinovirus upregulate genes associated with asthma susceptibility.

(A) Experimental design of the Helling et al. dataset consisting of basal bronchial epithelial cells from healthy donors stimulated with PBS or RV-A16.

(B) Volcano plot showing differentially expressed genes after rhinovirus infection, genes selected based on t-statistic are colored in purple.

(C) Bar plot showing LDSC-SEG heritability enrichment coefficient (τ^*) for each of the asthma-associated GWAS studies. Error bars represent $\tau^* \pm$ standard error. Asterisk denotes $P < 0.05$ and NS denotes nonsignificant ($P > 0.05$).

(D) Experimental design of the Basnet et al. time course dataset consisting of BECs stimulated with RV-C15.

(E) Bar plot showing LDSC-SEG heritability enrichment coefficient (t^*) for differentially expressed genes at each time point when compared against all others. Error bars represent $t^* \pm$ standard error. Asterisks denote significance as * $P < 0.05$, *** Bonferroni-adjusted $P < 0.05$ and NS denotes nonsignificant ($P > 0.05$).

Figure 2




Figure 2. scRNA-seq uncovers non-ciliated epithelial cells as potential mediators for asthma risk.

(A) Experimental design of the *Basnet et al.* scRNA-seq dataset of BECs from healthy donors infected with RV-C15.

(B) UMAP visualization of the 10,721 airway epithelial cells colored by cell type.

(C) scDRS results represented on the UMAP for the 4 asthma-associated GWAS tested. The intensity of the color represents the disease relevant score, the lighter purple represents a less intense score whereas a more intense purple represents cells associated with a stronger score. nonsignificant cells with a FDR higher than 10% are depicted in gray.

(D) Bar plot representing the percentage of each cell type in all cells followed by the significant cells at 10% FDR for scDRS in COA, Allergy/Eczema, All asthma. AOA is not represented on this barplot because no cells were significant.

Figure 3




Figure 3. RV-infected BECs from asthma patients showed a stronger enrichment for asthma risk compared to those of healthy individuals.

(A) Experimental design of *Helling et al.* dataset consisting of BECs from asthma patients stimulated with PBS or RV-A16.

(B) Volcano plot showing differentially expressed genes after rhinovirus infection in patient samples. Genes upregulated after infection were selected based on t-statistic and are colored in burgundy.


(C) Bar plot showing LDSC-SEG heritability enrichment coefficient (τ^*) across GWAS studies. Error bars represent $\tau^* \pm$ standard error. Asterisks denote significance as *** Bonferroni-adjusted $P < 0.05$ and NS denotes nonsignificant ($P > 0.05$).

(D) Volcano plot showing differentially expressed genes between asthma patients and healthy donors. Genes upregulated in patients were selected based on t-statistic and are colored in blue.

(E) Bar plot of LDSC-SEG heritability enrichment coefficient (τ^*), suggestively significant enrichment is labeled. Error bars represent $\tau^* \pm$ standard error. NS denotes nonsignificant ($P > 0.05$).

Figure 4

A



B
 bioRxiv preprint doi: <https://doi.org/10.1101/2024.02.02.24302068>; this version posted February 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




Figure 4. Rhinovirus induced genes that are found in COA and AOA GWAS.

(A) Miami plot of COA and AOA GWAS. Each gray dot shows the SNP found in the *Ferreira et al.*, GWAS. The black circles represent SNPs being found as lead variants in either Open Targets Genetics or in Ferreira study. Highlighted genes are upregulated upon rhinovirus infection, in purple the genes being L2G genes, in blue the closest one to the transcription start site of the variant (Open Target Genetics), and in black genes found in a window of 250kb around the SNP. The blue dashed line represents the P-value threshold of $-\log_{10}(5 \times 10^{-8})$.

(B) Box plots depicting gene expression levels for *MYC* (top) and *OVOL1* (bottom). Left panel shows gene expression in epithelial cells from the *Helling et al.* dataset; samples infected with RV-A16 are shown in green and non-infected samples are in brown. Right panel shows gene expression from *Gutierrez-Arcelus et al.* in activated CD4 memory T cells; colors depict time points after activation. In each plot every point represents an individual sample.

Figure 5




Figure 5. Influence from other viruses on asthma genetics.

(A) Experimental design of *Tao et al.* bulk RNA-seq dataset.

(B) Bar plot representing LDSC-SEG enrichment. Error bars represent τ^* +/- standard error. Asterisk denotes significance as * $P < 0.05$.

(C) Experimental design of *Ziegler et al.* single-cell RNA-seq dataset of epithelial cells infected with SARS-CoV-2 or not.


(D) UMAP visualization of the 32,588 cells colored by cell type.

(E) scDRS results represented on the UMAP for the 4 asthma-associated GWAS tested. The intensity of the color represents the disease relevant score, the lighter purple represents a less intense score whereas a more intense purple represents cells associated with a stronger score. nonsignificant cells with a FDR higher than 10% are depicted in gray.

(F) Bar plot representing the percentage of each cell type in all cells followed by the significant cells at 10% FDR for scDRS in AOA, COA, Allergy/Eczema and All asthma.

(G) Bar plot representing the percentage of cells in the full dataset coming from patients grouped by COVID severity categories (COVID-19, long COVID-19, respiratory failure) or from healthy donors (normal). Followed by percentage of cells passing significance at 10% FDR for AOA, COA, Allergy/Eczema, All asthma, by disease severity category or control.

Figure 6



medRxiv preprint doi: <https://doi.org/10.1101/2024.02.02.24302068>; this version posted February 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 6. Cytokines impact on asthma-associated genes.


(A) Experimental design of the *Koh et al.* bulk RNA-seq dataset of BECs from healthy donors that were stimulated or not with different cytokines (IFN γ , IFN α , IL-13, IL-17).

(B) Bar plot representing LDSC-SEG heritability enrichment coefficient (τ^*) for genes up-regulated in each stimuli against all others, for each of the asthma-associated GWAS. Error bars represent $\tau^* \pm$ standard error. NS denotes nonsignificant ($P > 0.05$).

(C) Experimental design of bulk RNA-seq of AECs from healthy donors co-stimulated with IL-4 and IL-13.

(D) Bar plot showing LDSC-SEG enrichment for each of the asthma-associated GWAS. Error bars represent $\tau^* \pm$ standard error. NS denotes nonsignificant ($P > 0.05$)

Supplementary Figure 1



Supplementary Figure 1. Validation of T cells enrichment in asthma-associated loci using differentially accessible peaks.

(A) Experimental design of the Calderon et al. ATAC-seq dataset of immune cell types that were activating or not *in vitro*.


(B) Volcano plot showing differentially expressed peaks between T cells and all other cell types. Peaks upregulated in T cells were selected based on t-statistic and are colored in green.

(C) Bar plots representing LDSC-SEG heritability enrichment coefficient (τ^*) for each cell type for the 3 control traits tested.

(D) Bar plot representing LDSC-SEG heritability enrichment coefficient (τ^*) for each set of cell-type-specific differentially accessible peaks for each of the asthma-associated traits.

(E) Bar plots showing LDSC-SEG heritability enrichment coefficient (τ^*) for each of the asthma-associated traits in cell-state-specific DA peaks of immune cells divided in either resting (light colors) or activated (dark colors) condition. In all bar plots, error bars represent $\tau^* \pm$ standard error and asterisks denote significance as *** Bonferroni-adjusted $P < 0.05$, ** FDR 5%, * $P < 0.05$, and NS denotes nonsignificant ($P > 0.05$).

Supplementary Figure 2



Supplementary Figure 2. T cell validation at the single-cell RNA-seq level.

(A) Experimental design of the *Wang et al.* scRNA-seq dataset of sinonasal mucosa from healthy donors and chronic rhinosinusitis patients (CRS).

(B) UMAP visualization of the 1,115,856 immune and non-immune cells colored by cell type.


(C) scDRS results represented on the UMAP for the 3 control GWAS tested. The intensity of the color represents the disease relevant score, the lighter purple represents a less intense score whereas a more intense purple represents cells associated with a stronger score. Non-significant cells with a FDR higher than 10% are depicted in gray.

(D) Bar plot representing the percentage of each cell type in all cells followed by the significant cells at 10% FDR for scDRS in Alzheimer's Disease, Height and Rheumatoid Arthritis.

(E) scDRS results represented on the UMAP for the 4 asthma-associated traits tested. The intensity of the color represents the disease relevant score, the lighter color represents a less intense score whereas a more intense color represents cells associated with a stronger score.

(F) Bar plot representing the percentage of each cell type in all cells followed by the significant cells at 10% FDR for scDRS in COA, Allergy/Eczema and All asthma.

Supplementary Figure 3



Supplementary Figure 3. Th2 validation at the single-cell RNA-seq level.


(A) Experimental design of the *Seumois et al.* scRNA-seq dataset consisting of T cells.

(B) UMAP visualization of the 38,559 T cells colored by subtypes.


(C) scDRS results represented on the UMAP for the 4 asthma-associated GWAS tested. The intensity of the color represents the disease relevant score, the lighter color represents a less intense score whereas a more intense color represents cells associated with a stronger score. nonsignificant cells with a FDR higher than 10% are depicted in gray.

Supplementary Figure 4


A



B



C




Supplementary Figure 4. Control traits of BECs from healthy individuals infected with RV.

(A) Bar plots representing LDSC-SEG heritability enrichment coefficient (τ^*) for the 3 control traits. NS denotes nonsignificant ($P > 0.05$).

(B) Volcano plots showing differentially expressed genes at each time point (12,24,42) compared to all others in RV-infected epithelial cells colored in yellow, orange and brown respectively.

(C) Bar plot representing LDSC-SEG heritability enrichment coefficient (τ^*) for each time point against all others for each of the control trait tested. NS denotes nonsignificant ($P > 0.05$). In all bar plots, error bars represent $\tau^* \pm$ standard error.

Supplementary Figure 5



Supplementary Figure 5. Additional informations related to Figure 2.

UMAP visualization of the 10,721 epithelial cells colored by **(A)** cell type. **(B)** donor.


(C) infection status (Infected / Non-infected).

(D) Dot plot representing the normalized average expression and the percent of cells expressing a given gene for epithelial cell markers.

(E) scDRS results represented on the UMAP for the 3 control GWAS tested. nonsignificant cells with a FDR higher than 10% are depicted in gray.

(F-I) Harmonized UMAP representing *CDHR3*, *RVC15*, *LAGLS9* and *SORL1* normalized expressions.

Supplementary Figure 6




Supplementary Figure 6. Control traits of BECs from asthma patients infected with RV.

Bar plots representing LDSC-SEG heritability enrichment coefficient (τ^*) for the 3 control traits tested. NS denotes nonsignificant ($P > 0.05$). **(A)** Using DE genes after RV-infection in epithelial cells from patients.

(B) Using genes differentially expressed in asthmatics when compared to healthy individuals. **(C)** Bar plot showing LDSC-SEG heritability enrichment coefficient (τ^*) across traits for genes downregulated upon RVC-15 infection. NS denotes nonsignificant ($P > 0.05$). In all bar plots, error bars represent $\tau^* \pm$ standard error.


Supplementary Figure 7



Supplementary Figure 7. Normalized expressions of gene of interest.

(A) Normalized expression of genes of interest represented on the UMAP and **(B)** on the harmonized UMAP.

Supplementary Figure 8



medRxiv preprint doi: <https://doi.org/10.1101/2024.02.02.24302068>; this version posted February 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


Supplementary Figure 8. Volcano plot and controls traits related to Figure 5.

(A) Volcano plot showing differentially expressed genes between influenza infection and control. Genes upregulated upon influenza infection were selected based on t-statistic and are colored in black.

(B) Bar plots representing LDSC-SEG heritability enrichment coefficient (τ^*) for the 3 control GWAS tested. Error bars represent $\tau^* \pm$ standard error. NS denotes nonsignificant ($P > 0.05$).

(C) scDRS results represented on the UMAP for the 3 control traits tested. The intensity of the color represents the disease relevant score, the lighter color represents a less intense score whereas a more intense color represents cells associated with a stronger score. nonsignificant cells with a FDR higher than 10% are depicted in gray.

Supplementary Figure 9



Supplementary Figure 9. scRNA-seq analysis of BECs infected or not with SARS-CoV-2.

(A) Experimental design of the *Ravindra et al.* scRNA-seq dataset of bronchial epithelial cells infected with SARS-CoV-2 or not, from one healthy donor.


UMAP visualization of the 74,088 cells colored by **(B)** days after virus infection and **(C)** by cell type.

(D) scDRS results represented on the UMAP for the 3 control traits tested. The intensity of the color represents the disease relevant score, the lighter color represents a less intense score whereas a more intense color represents cells associated with a stronger score. nonsignificant cells with a FDR higher than 10% are depicted in gray.

(E) Bar plot representing the percentage of each cell type in all cells followed by the significant cells at 10% FDR for scDRS in AOA, COA, Allergy/Eczema and All Asthma.

(F) Bar plot representing the percentage of cells in the full dataset classified in SARS-CoV-2 infection or non infected, followed by percentage of cells passing significance at 10% FDR for AOA, COA, Allergy/Eczema, All asthma, by SARS-CoV-2 infection or not.

Supplementary Figure 10



medRxiv preprint doi: <https://doi.org/10.1101/2024.02.02.24302068>; this version posted February 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplementary Figure 10. Control traits for Figure 6.

(A) Volcano plots showing differentially expressed genes for each stimuli (IFN α , IFN γ , IL-13 and IL-17) compared to all others in bronchial epithelial cells colored in black, teal, orange and brown respectively.

(B) Bar plot representing LDSC-SEG enrichment for each stimuli against all others for each of the 3 control traits. Error bars represent τ^* +/- standard error. Asterisk denotes significance as * $P < 0.05$ and NS denotes nonsignificant ($P > 0.05$).

(D) Volcano plot showing differentially expressed genes between IL-4/IL-13 stimulation and resting condition. Genes upregulated upon IL-4/IL-13 stimulation were selected based on t-statistic and are colored in green.

(E) Bar plots representing LDSC-SEG heritability enrichment coefficient (τ^*) for the 3 control traits. Error bars represent τ^* +/- standard error. Asterisk denotes significance as * $P < 0.05$ and NS denotes nonsignificant ($P > 0.05$).